Residency · Residency · Endocrinology

Type 2 Diabetes - Oral and Injectable Therapies

Pathophysiology

The "Ominous Octet" (DeFronzo)

The pathogenesis of type 2 diabetes mellitus (T2D) is far more complex than the historical model of simple insulin resistance and beta-cell failure. Ralph DeFronzo's conceptual framework of the "ominous octet" describes eight distinct pathophysiological defects that contribute to hyperglycemia, each of which represents a potential therapeutic target. First, progressive beta-cell dysfunction and eventual loss constitute the central defect; amyloid deposition (islet amyloid polypeptide), chronic glucotoxicity, and lipotoxicity from elevated free fatty acids collectively impair insulin secretion and accelerate beta-cell apoptosis. Second, increased hepatic glucose production driven by hepatic insulin resistance results in unchecked gluconeogenesis, particularly in the fasting state. Third, decreased peripheral glucose uptake reflects skeletal muscle insulin resistance, characterized by impaired GLUT4 translocation to the cell membrane and reduced glycogen synthesis. Fourth, increased lipolysis from adipose tissue insulin resistance elevates circulating free fatty acids, which in turn exacerbate both hepatic and skeletal muscle insulin resistance through lipotoxic mechanisms. Fifth, a diminished incretin effect manifests as reduced GLP-1 secretion from intestinal L-cells and resistance to glucose-dependent insulinotropic polypeptide (GIP) at the beta-cell level. Sixth, paradoxical hyperglucagonemia results from alpha-cell dysfunction, with inappropriately elevated postprandial glucagon secretion further driving hepatic glucose output. Seventh, increased renal glucose reabsorption occurs through upregulation of SGLT2 expression in the proximal tubule, raising the renal threshold for glucosuria and thereby perpetuating hyperglycemia. Eighth, neurotransmitter dysfunction in the central nervous system, specifically hypothalamic insulin resistance and altered appetite regulatory pathways, contributes to both metabolic dysregulation and the obesity that frequently accompanies T2D.

Natural History

The natural history of type 2 diabetes follows a predictable trajectory that unfolds over years to decades. Insulin resistance, the earliest detectable abnormality, typically precedes the development of overt hyperglycemia by many years, during which compensatory hyperinsulinemia maintains euglycemia. As beta-cell function progressively declines, the capacity to compensate becomes exhausted, and glucose tolerance deteriorates through a continuum from normal glucose tolerance to prediabetes (impaired fasting glucose and/or impaired glucose tolerance) and ultimately to overt diabetes. The landmark United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that beta-cell function is already reduced to approximately 50% of normal capacity at the time of T2D diagnosis and continues to decline at a rate of roughly 4-5% per year regardless of therapy. This relentless progression explains why most patients require treatment intensification over time and why many eventually transition to insulin-requiring diabetes.

Genetic and Environmental Factors

Type 2 diabetes has a strong genetic component, as evidenced by concordance rates of 60-90% in monozygotic twins, substantially higher than those observed in type 1 diabetes. Genome-wide association studies (GWAS) have identified over 400 genetic loci associated with T2D susceptibility, and intriguingly, the majority of these loci affect beta-cell function rather than insulin resistance, underscoring the primacy of secretory failure in disease pathogenesis. Key environmental factors that modulate genetic predisposition include obesity (particularly visceral adiposity, which is most strongly correlated with insulin resistance), sedentary lifestyle, consumption of a Western diet rich in refined carbohydrates and saturated fats, chronic sleep deprivation, and psychosocial stress. Importantly, these environmental factors are modifiable. The Diabetes Prevention Program (DPP) provided landmark evidence that intensive lifestyle intervention (achieving 7% weight loss combined with 150 minutes per week of moderate-intensity exercise) reduced progression from prediabetes to T2D by 58%, compared with a 31% reduction achieved with metformin alone. The DPP Outcomes Study confirmed that these benefits were sustained over more than 10 years of follow-up, firmly establishing lifestyle modification as the most effective primary prevention strategy.

Glycemic Targets and Treatment Approach

ADA/EASD 2022 Consensus: Person-Centered Approach

The 2022 American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) consensus report marked a paradigm shift in the approach to T2D pharmacotherapy, moving decisively from a glucocentric algorithm to a person-centered framework that prioritizes cardiorenal risk reduction and weight management alongside glycemic control. The general HbA1c target remains less than 7.0% for most non-pregnant adults, but individualization is essential: tighter targets (6.0-6.5%) may be appropriate for younger patients with short disease duration and low complication risk, whereas less stringent targets (7.5-8.0% or higher) are reasonable for elderly patients, those with limited life expectancy, extensive comorbidities, or high hypoglycemia risk. Treatment selection is now driven primarily by the presence or absence of specific comorbidities. For patients with established atherosclerotic cardiovascular disease (ASCVD) or high cardiovascular risk, a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit should be prescribed regardless of baseline HbA1c or concurrent metformin use. For patients with heart failure, an SGLT2 inhibitor is recommended regardless of HbA1c. For patients with chronic kidney disease (CKD), an SGLT2 inhibitor (if eGFR permits) and/or finerenone should be initiated, with a GLP-1 receptor agonist as an alternative or addition. When weight management is the priority, GLP-1 receptor agonists (particularly semaglutide and tirzepatide) are preferred for their superior weight reduction efficacy, while SGLT2 inhibitors offer more modest weight loss.

Pharmacologic Therapies

Metformin

Metformin, a biguanide that has been in clinical use for over six decades, exerts its glucose-lowering effect through multiple mechanisms. It activates AMP-activated protein kinase (AMPK), the cell's master energy sensor, leading to decreased hepatic glucose production through suppression of gluconeogenesis, modest improvement in peripheral insulin sensitivity, and reduced intestinal glucose absorption. Dosing typically begins at 500 mg once or twice daily and is gradually titrated to a maximum of 1000 mg twice daily (maximum 2550 mg/day), with extended-release formulations available to mitigate gastrointestinal side effects. Metformin achieves an HbA1c reduction of approximately 1.0-1.5%, and its advantages include weight neutrality or modest weight loss (approximately 2 kg), an absence of intrinsic hypoglycemia risk, very low cost, an extensive long-term safety record, and a potential cardiovascular benefit suggested by the UKPDS.

Gastrointestinal side effects including diarrhea, nausea, and abdominal bloating affect 20-30% of patients but generally improve with slow dose titration and use of extended-release formulations. Metallic taste is an occasional complaint. Chronic use leads to vitamin B12 deficiency in 5-10% of patients through impaired intestinal absorption, warranting periodic monitoring of B12 levels, particularly in patients with peripheral neuropathy where B12 deficiency may be a confounding or contributing factor. Lactic acidosis, the most feared complication, is exceedingly rare (approximately 4.3 per 100,000 patient-years) and almost exclusively occurs in the setting of predisposing conditions such as significant renal impairment, hepatic failure, circulatory shock, or iodinated contrast administration. Current contraindications include an eGFR below 30 mL/min/1.73m2 (at which point metformin should be discontinued) and initiation is not recommended when eGFR is below 45. Metformin should be held for iodinated contrast procedures when eGFR is below 60 or during acute illness. Notably, the 2022 ADA/EASD consensus no longer universally recommends metformin as the mandatory first-line agent; in patients with compelling cardiorenal comorbidities, SGLT2 inhibitors or GLP-1 receptor agonists may be initiated first or concurrently.

SGLT2 Inhibitors

The sodium-glucose cotransporter 2 (SGLT2) inhibitors represent one of the most consequential advances in diabetes pharmacotherapy. These agents inhibit SGLT2 in the proximal renal tubule, which is responsible for approximately 90% of filtered glucose reabsorption, thereby inducing therapeutic glycosuria of approximately 70-80 grams per day. Available agents include empagliflozin (Jardiance, 10-25 mg daily), dapagliflozin (Farxiga, 5-10 mg daily), canagliflozin (Invokana, 100-300 mg daily), and ertugliflozin (Steglatro, 5-15 mg daily). The class achieves an HbA1c reduction of 0.5-1.0%, along with consistent weight loss of 2-3 kg attributable to caloric loss through glycosuria and a systolic blood pressure reduction of 3-5 mmHg mediated by osmotic diuresis and natriuresis.

Landmark Cardiovascular and Renal Trials

The cardiovascular and renal outcome data for SGLT2 inhibitors have fundamentally transformed diabetes management and expanded their indications far beyond glucose lowering. The EMPA-REG OUTCOME trial demonstrated that empagliflozin reduced three-point MACE by 14%, heart failure hospitalization by 35%, and cardiovascular death by 38% in patients with established ASCVD. The CANVAS program showed a 14% reduction in three-point MACE with canagliflozin, though an initially observed increase in amputation risk was not subsequently confirmed in the CREDENCE trial. DECLARE-TIMI 58 with dapagliflozin demonstrated a reduction in heart failure hospitalization, though the cardiovascular death reduction did not reach statistical significance for the broader MACE endpoint. Perhaps most transformatively, the DAPA-HF and EMPEROR-Reduced trials demonstrated that SGLT2 inhibitors reduced heart failure hospitalization and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF) regardless of diabetes status, establishing these agents as standard of care for HFrEF. The DELIVER and EMPEROR-Preserved trials subsequently extended this benefit to heart failure with preserved ejection fraction (HFpEF). On the renal front, the DAPA-CKD, CREDENCE, and EMPA-KIDNEY trials collectively demonstrated that SGLT2 inhibitors slow CKD progression regardless of diabetes status, establishing them as standard therapy for CKD with albuminuria at eGFR levels above 20-25 mL/min/1.73m2. The renal protective mechanism involves afferent arteriolar vasoconstriction mediated by restored tubuloglomerular feedback, which reduces intraglomerular pressure. An acute eGFR "dip" of 3-5 mL/min is expected upon initiation, reflects the hemodynamic effect, and should not prompt drug discontinuation, as long-term renoprotection is well established.

Side Effects

The side effect profile of SGLT2 inhibitors is generally manageable but includes several important considerations. Genital mycotic infections occur in 5-10% of patients (more frequently in women) and typically respond to topical antifungal therapy and improved hygiene practices. Urinary tract infections show a modest increase, again predominantly in women. Volume depletion with orthostatic hypotension can occur, particularly in elderly patients or those on concurrent diuretic therapy, and may necessitate reduction of loop diuretic doses. Diabetic ketoacidosis in a euglycemic presentation is a rare (approximately 0.1%) but serious complication in which blood glucose may be near-normal (below 250 mg/dL), making the diagnosis easily missed. Risk factors include off-label use in type 1 diabetes, perioperative states, acute illness, low-carbohydrate diets, insulin dose reduction, and excessive alcohol consumption. Current guidance recommends holding SGLT2 inhibitors 3-4 days before major surgery. Fournier gangrene (necrotizing fasciitis of the perineum) is exceedingly rare but carries an FDA warning, and patients should be counseled regarding symptoms. An amputation signal was observed with canagliflozin in the CANVAS trial but was not confirmed in subsequent studies, and a modest signal for bone fracture risk was similarly limited to canagliflozin.

<image>A comprehensive comparison infographic of the major diabetes drug classes. Create a table/grid format with rows for each drug class: Metformin, SGLT2i, GLP-1 RA, GIP/GLP-1 RA (tirzepatide), DPP-4i, Sulfonylureas, TZDs, and Insulin. Columns should include: mechanism of action (with a simple cell diagram), HbA1c reduction (%), weight effect (kg change), hypoglycemia risk (low/moderate/high), CV benefit (yes/no with trial name), renal benefit (yes/no), key side effects, and relative monthly cost ($-$$$$). Use color coding: green for favorable attributes, yellow for neutral, red for unfavorable. Include small icons for each mechanism of action.</image>

GLP-1 Receptor Agonists (GLP-1 RA)

The GLP-1 receptor agonists are injectable (and now oral) peptide analogs that activate the GLP-1 receptor, producing glucose-dependent insulin secretion from beta cells, suppression of inappropriately elevated glucagon, delayed gastric emptying (contributing to postprandial glucose control), and promotion of satiety through direct hypothalamic action. This class achieves HbA1c reductions of 1.0-1.8% and weight loss ranging from 3-7 kg with standard-dose injectable formulations to up to 15% of body weight with high-dose semaglutide, making GLP-1 RAs among the most effective non-insulin glucose-lowering agents available.

Agents

The available GLP-1 RAs span a range of pharmacokinetic profiles and administration schedules. Exenatide (Byetta), the first-in-class agent, is an exendin-4-based peptide with 50% homology to native GLP-1, administered as 5-10 mcg subcutaneously twice daily. Exenatide extended-release (Bydureon) employs microsphere technology to deliver 2 mg subcutaneously once weekly. Liraglutide (Victoza) achieves 97% GLP-1 homology with an albumin-binding fatty acid chain that extends the half-life to approximately 13 hours, dosed at 0.6-1.8 mg subcutaneously daily. Dulaglutide (Trulicity) is an Fc-GLP-1 fusion protein administered at 0.75-4.5 mg subcutaneously weekly. Semaglutide subcutaneous (Ozempic) represents the highest-potency agent in the class, featuring a fatty acid chain modification that confers a half-life of approximately 7 days, dosed at 0.25-2.0 mg weekly. Oral semaglutide (Rybelsus) utilizes the SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) absorption enhancer to enable oral bioavailability, dosed at 3-14 mg daily with specific instructions to take on an empty stomach with no more than 4 ounces of water, followed by a 30-minute fast from food, drink, and other oral medications. Lixisenatide (Adlyxin) is a short-acting agent primarily targeting postprandial glucose excursions, dosed at 10-20 mcg subcutaneously daily.

Cardiovascular Outcome Trials

The cardiovascular outcome trial program for GLP-1 RAs has produced some of the most practice-changing evidence in modern diabetology. The LEADER trial demonstrated that liraglutide reduced three-point MACE by 13% and cardiovascular death by 22% in patients with T2D and high cardiovascular risk. SUSTAIN-6 showed that subcutaneous semaglutide achieved a 26% reduction in three-point MACE, driven primarily by stroke reduction. The REWIND trial extended the cardiovascular benefit of dulaglutide to a broader population in which only 31% had established ASCVD, with a 12% reduction in three-point MACE. The SELECT trial was particularly transformative, demonstrating a 20% reduction in MACE with semaglutide 2.4 mg in overweight and obese patients without diabetes, suggesting anti-atherosclerotic effects that extend beyond glucose lowering. The SOUL trial confirmed cardiovascular benefit for the oral semaglutide formulation. AMPLITUDE-O demonstrated a 27% reduction in a composite of MACE and renal endpoints with efpeglenatide. Most recently, the FLOW trial became the first dedicated renal outcome trial for a GLP-1 RA, showing a 24% reduction in kidney disease progression with semaglutide in patients with T2D and CKD.

Side Effects

Gastrointestinal side effects are the most common limitation of GLP-1 RAs, with nausea occurring in 20-40% of patients, along with vomiting and diarrhea. These effects are dose-dependent and typically attenuate with slow dose titration over several weeks. Injection site reactions occur particularly with exenatide extended-release, which can produce subcutaneous nodules. Pancreatitis, while the subject of considerable early concern, occurs at a small absolute risk increase of approximately 0.1-0.3%; patients should be monitored for suggestive symptoms and the drug discontinued if pancreatitis is confirmed. Gallbladder disease, including cholelithiasis and cholecystitis, is increased and likely related to rapid weight loss. Thyroid C-cell tumors (medullary thyroid carcinoma) have been observed in rodent studies, though human relevance remains uncertain; a boxed warning exists, and the class is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. A signal for retinopathy worsening was observed with semaglutide in SUSTAIN-6, attributed to rapid HbA1c reduction in patients with pre-existing retinopathy, and ophthalmologic screening is recommended before initiation in such patients. Concern regarding loss of lean muscle mass during significant weight reduction has emerged, and concurrent resistance training is recommended to preserve skeletal muscle.

GIP/GLP-1 Receptor Agonist (Dual Incretin)

Tirzepatide (Mounjaro) represents a first-in-class glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor dual agonist, administered at 5, 10, or 15 mg subcutaneously weekly. This dual incretin approach achieves unprecedented glucose lowering with HbA1c reductions of up to 2.4% in the SURPASS trial program, making it the most potent glucose-lowering injectable available. Weight loss is equally remarkable, reaching up to 22% of body weight (approximately 25 kg) in the SURMOUNT-1 trial in patients with obesity without diabetes. Across the SURPASS-1 through SURPASS-5 trials, tirzepatide demonstrated superiority to semaglutide 1 mg, insulin glargine, and insulin degludec for HbA1c reduction. The SURPASS-CVOT cardiovascular outcome trial is ongoing, with preliminary signals suggesting cardiovascular benefit. The side effect profile is similar to that of GLP-1 RAs, with nausea being the most common adverse effect, though gastrointestinal side effects may be slightly less pronounced than with equivalent-dose semaglutide. The contribution of GIP receptor agonism extends beyond incretin-mediated insulin secretion, potentially modifying fat distribution and exerting effects on bone metabolism that remain under active investigation.

DPP-4 Inhibitors (Gliptins)

The dipeptidyl peptidase-4 (DPP-4) inhibitors act by inhibiting the DPP-4 enzyme responsible for the rapid degradation of endogenous GLP-1 and GIP, thereby prolonging their circulating half-life by approximately two- to three-fold. Available agents include sitagliptin (Januvia, 100 mg daily with renal dose adjustments to 50 mg if eGFR 30-45 and 25 mg if eGFR below 30), saxagliptin (Onglyza, 2.5-5 mg daily), linagliptin (Tradjenta, 5 mg daily with no renal dose adjustment due to predominantly hepatic elimination), and alogliptin (Nesina, 25 mg daily with renal adjustments). The class achieves a modest HbA1c reduction of 0.5-0.8%, is weight-neutral, and carries a low risk of hypoglycemia. Cardiovascular outcome trials were uniformly neutral for MACE, though SAVOR-TIMI 53 with saxagliptin demonstrated an unexpected increase in heart failure hospitalization (hazard ratio 1.27), while TECOS (sitagliptin) and CARMELINA (linagliptin) were neutral for heart failure. Side effects are generally mild and include nasopharyngitis, headache, rare severe joint pain (arthralgia), and very rare bullous pemphigoid. In the current therapeutic landscape, the role of DPP-4 inhibitors has become limited given the availability of GLP-1 RAs, which provide far greater efficacy for glucose lowering, weight reduction, and cardiovascular risk reduction. DPP-4 inhibitors retain utility when GLP-1 RAs are not tolerated or accessible, or when a simple oral regimen is preferred.

Sulfonylureas

The sulfonylureas stimulate insulin secretion by binding to the SUR1 subunit of the ATP-sensitive potassium (KATP) channel on pancreatic beta cells, triggering channel closure, membrane depolarization, and calcium-mediated insulin exocytosis independently of ambient glucose concentration. Available agents include glipizide (2.5-20 mg daily or twice daily, short-acting, preferred in elderly patients), glimepiride (1-8 mg daily, longer-acting), and glyburide/glibenclamide (1.25-10 mg daily or twice daily, longest-acting with the highest hypoglycemia risk, which should be avoided in elderly patients and those with CKD). The class achieves HbA1c reductions of 1.0-1.5% but is associated with weight gain of 2-3 kg due to insulin-mediated anabolism and a significant risk of hypoglycemia, with 10-20% of patients experiencing hypoglycemic episodes, particularly with glyburide in elderly and renally impaired populations. The UKPDS demonstrated cardiovascular benefit with sulfonylureas, and the CAROLINA trial showed no difference in cardiovascular outcomes between linagliptin and glimepiride, providing some reassurance regarding cardiovascular safety. Sulfonylureas remain among the least expensive diabetes medications and are critically important for global diabetes care where access to newer agents is limited. However, in well-resourced settings, their use is declining due to hypoglycemia risk, weight gain, and the availability of safer alternatives with demonstrated cardiorenal benefits. Concerns regarding accelerated beta-cell exhaustion are supported by data from the ADOPT trial, in which sulfonylureas showed the fastest rate of secondary treatment failure (HbA1c rise) over time compared with metformin and rosiglitazone.

Thiazolidinediones (TZDs)

The thiazolidinediones are agonists of the peroxisome proliferator-activated receptor gamma (PPAR-gamma), a nuclear receptor predominantly expressed in adipose tissue that regulates genes involved in insulin sensitivity, adipocyte differentiation, and lipid metabolism. By promoting the differentiation of small, insulin-sensitive adipocytes and facilitating fat redistribution from visceral to subcutaneous depots, TZDs enhance insulin sensitivity in both adipose tissue and skeletal muscle. Pioglitazone (Actos, 15-45 mg daily) is the more widely used agent and offers potential cardiovascular benefit as suggested by the PROACTIVE trial, which showed reduction in a secondary composite endpoint of myocardial infarction and stroke. Pioglitazone also reduces hepatic steatosis and may have benefit in non-alcoholic steatohepatitis (NASH). Rosiglitazone (Avandia, 4-8 mg daily) generated significant concern following a meta-analysis by Nissen suggesting increased cardiovascular risk; although FDA restrictions were later removed after the RECORD trial did not confirm increased risk, rosiglitazone sees minimal current clinical use. The class achieves HbA1c reductions of 1.0-1.5% with no hypoglycemia risk and notably durable glucose lowering, as demonstrated in the ADOPT trial where TZDs showed the slowest rate of secondary treatment failure. However, side effects are substantial and include fluid retention and peripheral edema (contraindicated in NYHA class III-IV heart failure), bone fractures (approximately doubled risk, particularly in postmenopausal women), a debated small absolute risk of bladder cancer with pioglitazone, and macular edema. Current clinical use is largely confined to patients with significant insulin resistance, NASH, or those who cannot tolerate other agents.

Alpha-Glucosidase Inhibitors

The alpha-glucosidase inhibitors (acarbose, voglibose, miglitol) inhibit the brush-border alpha-glucosidase enzymes in the small intestine, delaying the digestion of complex carbohydrates and thereby attenuating postprandial glucose excursions. Acarbose is dosed at 25-100 mg three times daily, taken with the first bite of each meal. The class achieves a modest HbA1c reduction of 0.5-0.8% and is limited primarily by gastrointestinal side effects including flatulence, bloating, and diarrhea, which result from undigested carbohydrate reaching the colon and significantly limit adherence. Starting at a low dose and titrating slowly can improve tolerability. These agents have a limited role in current Western practice but retain some use in Asian countries where diets are carbohydrate-rich and postprandial hyperglycemia tends to predominate.

Insulin in Type 2 Diabetes

As type 2 diabetes is a progressive disease characterized by inexorable beta-cell decline, approximately 50% of patients eventually require exogenous insulin therapy. Initiation of basal insulin should be considered when HbA1c exceeds 10%, fasting glucose is consistently above 300 mg/dL, symptoms of hyperglycemia are present, or glycemic targets are not achieved despite two to three optimized oral and/or injectable agents. A typical starting dose is 0.1-0.2 units/kg/day (or a fixed 10 units), titrated upward by 2-4 units every 3-7 days to achieve the fasting glucose target. Importantly, metformin should be continued with insulin as it reduces insulin dose requirements by approximately 20%, and SGLT2 inhibitors and/or GLP-1 RAs should be maintained for their independent cardiorenal benefits. Prandial insulin should only be added if HbA1c remains above target on an optimized basal insulin regimen, using either a basal-plus approach (one prandial dose at the largest meal) or a full basal-bolus regimen.

<image>A step-wise treatment algorithm for type 2 diabetes based on ADA/EASD 2022 consensus. Start with lifestyle modification (diet, exercise, weight management) as the foundation. First-line pharmacotherapy layer: decision tree based on comorbidities - if established ASCVD leads to GLP-1 RA or SGLT2i with proven benefit; if heart failure leads to SGLT2i; if CKD leads to SGLT2i and/or GLP-1 RA plus finerenone; if weight management priority leads to GLP-1 RA (semaglutide/tirzepatide). If no compelling comorbidity, metformin as initial therapy. Intensification layer: add agents based on additional needs (further HbA1c reduction, weight loss, cost considerations). Final layer: insulin (basal, then basal-bolus if needed). Use a layered pyramid or stepped diagram with color-coded pathways for each clinical scenario.</image>

Emerging and Novel Therapies

Oral GLP-1 Receptor Agonists

Oral semaglutide (Rybelsus) established proof of concept for oral peptide delivery in diabetes therapy, though its clinical utility is somewhat limited by the requirement for fasting administration and significant absorption variability. Next-generation oral GLP-1 RAs are in advanced development and promise to overcome these limitations. Oral orforglipron (Eli Lilly) is a non-peptide, small-molecule GLP-1 receptor agonist currently in Phase 3 trials that does not require fasting for administration, potentially offering a more convenient oral option with GLP-1 RA-class efficacy. Danuglipron (Pfizer) is another non-peptide oral GLP-1 RA in development.

Dual and Triple Agonists

The therapeutic landscape is rapidly expanding beyond single-incretin agonism. Tirzepatide, the GIP/GLP-1 dual agonist, is now approved and has assumed a dominant position. Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, is in Phase 3 development and has demonstrated weight loss of up to 24% along with significant hepatic fat reduction attributable to the glucagon receptor component, which enhances hepatic lipid oxidation and energy expenditure. Survodutide, a GLP-1/glucagon dual agonist, has shown particular promise for NASH/MASH and weight management.

Other Pipeline Agents

Additional novel agents in the pipeline include aldosterone synthase inhibitors being investigated for diabetic kidney disease, and GLP-1/amylin co-agonists such as CagriSema (a combination of semaglutide and cagrilintide) that have demonstrated superior weight loss compared to semaglutide alone by leveraging the complementary satiety signals of GLP-1 and amylin.

Key Clinical Pearls

• SGLT2 inhibitors and GLP-1 RAs should be prioritized for patients with established ASCVD, heart failure, or CKD regardless of HbA1c; their cardiorenal benefits are independent of glucose lowering
• Tirzepatide (GIP/GLP-1 dual agonist) is the most potent glucose-lowering and weight-reducing injectable; head-to-head superior to semaglutide 1 mg in SURPASS-2
• Euglycemic DKA with SGLT2 inhibitors is a critical entity to recognize; hold SGLT2i 3-4 days before major surgery and during acute illness; glucose may be deceptively normal
• Metformin's role as universal first-line therapy has been reevaluated; in patients with compelling cardiorenal indications, SGLT2i or GLP-1 RA may be started first (or simultaneously)
• Sulfonylureas remain important for global diabetes care due to low cost and effectiveness, but in well-resourced settings, safer alternatives with cardiorenal benefits are preferred
• The SELECT trial extended semaglutide's proven CV benefit to overweight/obese patients WITHOUT diabetes, suggesting anti-atherosclerotic effects beyond glucose lowering

References

1. Davies MJ, et al. "Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by ADA and EASD." Diabetes Care. 2022;45(11):2753-2786.
2. Zinman B, et al. "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME)." N Engl J Med. 2015;373(22):2117-2128.
3. Marso SP, et al. "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)." N Engl J Med. 2016;375(4):311-322.
4. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." N Engl J Med. 2022;387(3):205-216.
5. Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT)." N Engl J Med. 2023;389(24):2221-2232.

Read this lecture as Markdown